Why Choose ADVATE?

Here's why you can choose ADVATE with confidence:

The first recombinant factor VIII therapy to be free of blood-based additives^1-3

Eliminates the potential risk of viruses that may be carried by blood-based additives,* because no plasma proteins are added at any stage of manufacturing^1-3

*There have been no confirmed reports of serious viral transmissions with recombinant factor VIII therapies.

A proven recombinant factor VIII therapy

Extensive clinical studies⁵
Based on the proven, full-length RECOMBINATE [Antihemophilic Factor (Recombinant)] molecule with a 15-year history^5-7
Over three billion IUs distributed to date^4†

A well-established record of safety and efficacy

Low rate of inhibitor development in clinical studies of PTPs^3,5
Proven efficacy to control bleeds—most managed with a single infusion in clinical studies^3,5,8

A fit for active lives

With continual improvements in dosage strengths, mixing, and portability, ADVATE fits in with today's active lives

Baxter is there for you

Demonstrated, ongoing commitment to the hemophilia community through solutions that come from listening to you

^† Worldwide, as of October 2007.

ADVATE supplied with BAXJECT II Full Prescribing Information

ADVATE supplied with Double Ended Needles Full Prescribing Information

References:

1. The National Hemophilia Foundation. MASAC Recommendations Concerning the Treatment of Hemophilia and Other Bleeding Disorders. MASAC Document #177. October 2006.

2. McCormack PL, Plosker GL. Octocog alpha, plasma/albumin-free method. Drugs. 2005;65:2613-2620.

3. ADVATE Prescribing Information. Westlake Village, CA: Baxter Healthcare Corporation; July 2007.

4. Data on File. Westlake Village, CA: Baxter Healthcare Corporation.

5. Shapiro AD. Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE®) in the management of hemophilia A. Vasc Health Risk Manag. 2007;3(5):555-565.

6. U.S. Food and Drug Administration. www.fda.gov/cber/pdufa/billable.htm. Accessed April 2008.

7. Ewenstein BM, Gomperts ED, Pearson S, O'Banian ME. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate®): a prospective pharmacovigilance study. Haemophilia. 2004;10:491-498.

8. Tarantino MD, Collins PW, Hay CRM, et al, and the rAHF-PFM Clinical Study Group. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia. 2004;10:428-437.

Why Choose ADVATE?

Here's why you can choose ADVATE with confidence:

eUpdates